Abingworth LLP reduced its position in CymaBay Therapeutics Inc (NASDAQ:CBAY) by 3.6% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,542,722 shares of the biopharmaceutical company’s stock after selling 57,278 shares during the period. CymaBay Therapeutics comprises 8.6% of Abingworth LLP’s holdings, making the stock its 4th largest position. Abingworth LLP owned about 3.52% of CymaBay Therapeutics worth $12,419,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of CBAY. Vanguard Group Inc. lifted its position in CymaBay Therapeutics by 20.7% during the second quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock worth $5,712,000 after acquiring an additional 170,126 shares during the last quarter. Citadel Advisors LLC acquired a new stake in CymaBay Therapeutics during the third quarter worth approximately $5,159,000. EAM Investors LLC acquired a new stake in CymaBay Therapeutics during the third quarter worth approximately $4,788,000. Omega Fund Management LLC lifted its position in CymaBay Therapeutics by 82.9% during the third quarter. Omega Fund Management LLC now owns 551,477 shares of the biopharmaceutical company’s stock worth $4,445,000 after acquiring an additional 250,000 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in CymaBay Therapeutics by 97.6% during the first quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock worth $997,000 after acquiring an additional 114,549 shares during the last quarter. Institutional investors and hedge funds own 69.12% of the company’s stock.

CBAY has been the subject of several research reports. Leerink Swann restated a “buy” rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Cantor Fitzgerald restated a “buy” rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a research report on Wednesday, November 8th. Oppenheimer set a $15.00 price objective on shares of CymaBay Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 30th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $12.00 price objective on shares of CymaBay Therapeutics in a research report on Friday, October 27th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. CymaBay Therapeutics has a consensus rating of “Buy” and an average price target of $14.50.

Shares of CymaBay Therapeutics Inc (NASDAQ CBAY) opened at $8.57 on Wednesday. The company has a current ratio of 7.39, a quick ratio of 7.39 and a debt-to-equity ratio of 0.04. CymaBay Therapeutics Inc has a 1 year low of $1.46 and a 1 year high of $9.40.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). During the same quarter in the prior year, the business posted ($0.25) EPS. equities analysts expect that CymaBay Therapeutics Inc will post -0.83 EPS for the current fiscal year.

In related news, Director Carl Goldfischer sold 18,000 shares of CymaBay Therapeutics stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $8.66, for a total value of $155,880.00. Following the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at $77,940. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kurt Von Emster sold 108,876 shares of CymaBay Therapeutics stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $7.85, for a total transaction of $854,676.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 447,257 shares of company stock valued at $3,730,862. 15.10% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “CymaBay Therapeutics Inc (CBAY) Shares Sold by Abingworth LLP” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/cymabay-therapeutics-inc-cbay-shares-sold-by-abingworth-llp/1746718.html.

CymaBay Therapeutics Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.